OpenAI announced on June 3, 2026, that it is bringing new capabilities to GPT-Rosalind, a model series purpose-built for life sciences research at enterprise scale. The update merges the agentic coding and tool use of its latest GPT-5.5 with stronger intelligence for drug discovery, analysis, design, and experimental workflows.
June 3, 2026 · OpenAI
GPT‑Rosalind gets a major upgrade for life sciences research
A domain‑specific reasoning model for biology and drug discovery now folds in GPT‑5.5's agentic coding and tool use — built to accelerate hypothesis generation, evidence integration, and experimental planning at the earliest, slowest stage of drug development.
10–15 yrs
Average time from target discovery to drug approval — the bottleneck it targets
6 / 11
LAB‑Bench2 tasks where it beat the prior GPT‑5.4
50+
Scientific tools & databases wired into the Codex research plugin
Dyno Therapeutics RNA task vs. human experts
Percentile rank against 57 historical scores from human experts (private sequence‑to‑function task).
Sequence generation 84th pct
Human expert median 50th pct
Takeaway: on prediction the model sits near the very top of the human distribution; on generation it still beats most experts.
A reasoning & orchestration layer across the workflow
Literaturereview & search
→
Databases & tools50+ via Codex
→
Design & analysisprotein, sequence, DNA
→
Experimental planningscientist in the loop
Positive reception
Called a "major upgrade" with better drug‑discovery intelligence
Integrates agentic coding, bio/chem reasoning and Codex tooling
Acts as a dynamic workbench keeping scientists in the loop
Gains in token efficiency and GeneBench performance
Caveats & access
Research preview — vetted U.S. enterprise customers only
API limited to internal research tools, not consumer apps
Skepticism over the narrow, trusted‑access rollout
SOC 2 Type 2, HIPAA‑aligned, RBAC; no training on customer data
Continue reading The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in ✓ Signed in — this article isn’t included in your current plan.Unlocking the full article…